Anfossi G, Trovati M, Mularoni E, Massucco P, Calcamuggi G, Emanuelli G
Institute of Internal Medicine, Clinica Medica III-University of Turin, Ospedale San Luigi Gonzaga, Orbassano, Italy.
Prostaglandins Leukot Essent Fatty Acids. 1989 Apr;36(1):1-7. doi: 10.1016/0952-3278(89)90154-3.
The beta-adrenoceptor antagonist propranolol is used in the therapy of hypertension and ischemic heart disease. The aim of our study was to evaluate the effects of this drug on platelet aggregation and on synthesis of thromboxane B2 (the stable metabolite of Thromboxane A2) from platelet rich plasma (PRP), whole blood samples and during spontaneous clotting. The results indicate that propranolol at concentrations near the therapeutic range, significantly inhibit collagen and thrombin-induced platelet aggregation and TxB2 synthesis from PRP. Furthermore the drug demonstrates inhibitory activity on B-TG release and TxB2 production from whole blood samples and on spontaneous clotting. The results suggest that some benefits of propranolol in the treatment of patients with coronary artery disease or cardiovascular conditions associated with platelet hyperaggregability may also be related to interference with platelet activation "in vivo" and with TxA2 generation.
β-肾上腺素能受体拮抗剂普萘洛尔用于治疗高血压和缺血性心脏病。我们研究的目的是评估该药物对血小板聚集以及富含血小板血浆（PRP）、全血样本和自发凝血过程中血栓素B2（血栓素A2的稳定代谢产物）合成的影响。结果表明，在接近治疗范围的浓度下，普萘洛尔可显著抑制PRP中胶原和凝血酶诱导的血小板聚集以及血栓素B2的合成。此外，该药物对全血样本中的β-血小板球蛋白释放和血栓素B2生成以及自发凝血具有抑制活性。结果表明，普萘洛尔在治疗冠状动脉疾病或与血小板高聚集性相关的心血管疾病患者中的一些益处，可能也与在“体内”干扰血小板活化和血栓素A2生成有关。
